TY - JOUR
T1 - Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance among Cognitively Normal Individuals
AU - Roe, Catherine M.
AU - Barco, Peggy P.
AU - Head, Denise M.
AU - Ghoshal, Nupur
AU - Selsor, Natalie
AU - Babulal, Ganesh M.
AU - Fierberg, Rebecca
AU - Vernon, Elizabeth K.
AU - Shulman, Neal
AU - Johnson, Ann
AU - Fague, Scot
AU - Xiong, Chengjie
AU - Grant, Elizabeth A.
AU - Campbell, Angela
AU - Ott, Brian R.
AU - Holtzman, David M.
AU - Benzinger, Tammie L.S.
AU - Fagan, Anne M.
AU - Carr, David B.
AU - Morris, John C.
N1 - Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Postmortem brain studies of older drivers killed in car accidents indicate that many had Alzheimer disease (AD) neuropathologic changes. We examined whether AD biomarkers are related to driving performance among cognitively normal older adults. Individuals with normal cognition, aged 65 + years, and driving at least once per week, were recruited. Participants (N129) took part in clinical assessments, a driving test, and positron emission tomography imaging with Pittsburgh compound B (PIB) andor cerebrospinal fluid (CSF) collection. General linear models tested whether the number of driving errors differed as a function of each of the biomarker variables (mean cortical binding potential for PIB, and CSF Aβ42, tau, ptau181, tauAβ42, ptau181Aβ42). Higher ratios of CSF tauAβ42, ptau181Aβ42, and PIB mean cortical binding potential, were associated with more driving errors (P<0.05). Preclinical AD may have subtle cognitive and functional effects, which alone may go unnoticed. However, when combined, these changes may impact complex behaviors such as driving.
AB - Postmortem brain studies of older drivers killed in car accidents indicate that many had Alzheimer disease (AD) neuropathologic changes. We examined whether AD biomarkers are related to driving performance among cognitively normal older adults. Individuals with normal cognition, aged 65 + years, and driving at least once per week, were recruited. Participants (N129) took part in clinical assessments, a driving test, and positron emission tomography imaging with Pittsburgh compound B (PIB) andor cerebrospinal fluid (CSF) collection. General linear models tested whether the number of driving errors differed as a function of each of the biomarker variables (mean cortical binding potential for PIB, and CSF Aβ42, tau, ptau181, tauAβ42, ptau181Aβ42). Higher ratios of CSF tauAβ42, ptau181Aβ42, and PIB mean cortical binding potential, were associated with more driving errors (P<0.05). Preclinical AD may have subtle cognitive and functional effects, which alone may go unnoticed. However, when combined, these changes may impact complex behaviors such as driving.
KW - Alzheimer disease
KW - cerebrospinal fluid biomarkers
KW - dementia
KW - driving
KW - imaging biomarkers
UR - http://www.scopus.com/inward/record.url?scp=84964612658&partnerID=8YFLogxK
U2 - 10.1097/WAD.0000000000000154
DO - 10.1097/WAD.0000000000000154
M3 - Article
C2 - 27128959
AN - SCOPUS:84964612658
SN - 0893-0341
VL - 31
SP - 69
EP - 72
JO - Alzheimer disease and associated disorders
JF - Alzheimer disease and associated disorders
IS - 1
ER -